You are here: Industry Insights > IND

News List

ContraVir Pharmaceuticals Submits IND for NASH Drug contractpharma
June 28, 2019
IND positions NASH as a second indication for CRV431, in addition to HBV.
Epygenix Submits IND Application for EPX-100 for Dravet Syndrome americanpharmaceuticalreview
June 26, 2019
Epygenix Therapeutics announced the Company has submitted Investigational New Drug Application (IND) and Fast Track Designation Request for EPX-100 to the U.S. Food and Drug Administration (FDA) for the treatment of patients with Dravet syndrome.
Aclaris Therapeutics Submits IND for RA Treatment contractpharma
June 14, 2019
If the IND is allowed by the FDA, Aclaris plans to initiate a Phase 1 trial of ATI-450, an oral MK2 inhibitor in 2H19
FDA Approves IND Application to Initiate Relapsed or Refractory AML Clinical Trial americanpharmaceuticalreview
May 30, 2019
BioTheryX announced the U.S. Food and Drug Administration (FDA) has cleared BioTheryX's investigational new drug application (IND) for BTX-A51, an oral multi-kinase inhibitor, for the treatment of patients with ...
Wellspring Biosciences Announces IND Clearance to Start Trial of ARS-3248 americanpharmaceuticalreview
May 22, 2019
Wellspring Biosciences announced the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for ARS-3248, a small molecule KRAS G12C inhibitor.
Wellspring Biosciences, Janssen Receive IND Clearance contractpharma
May 20, 2019
anssen Biotech will conduct the Phase I trial for ARS-3248, a small molecule KRAS G12C inhibitor.
Wellspring Biosciences Announces IND Application Clearance to Initiate ARS-3248 Trial americanpharmaceuticalreview
May 17, 2019
Wellspring Biosciences, a wholly owned subsidiary of Araxes Pharma, announced the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for ARS-3248 ...
Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat for the Treatment of NAFLD/NASH drugs
April 18, 2019
Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat for the Treatment of NAFLD/NASH
Tizona Therapeutics appoints Scott Clarke as CEO biospectrumasia
January 07, 2019
US based biotech company, Tizona Therapeutics has announced that Scott Clarke has joined the company as its chief executive officer. Clarke joins from Roche where he served as the Global Head of Oncology Partnering and Head of Asia 。。。
Bio-Thera Solutions Files IND for Phase 1 Clinical Trial with BAT8003 americanpharmaceuticalreview
December 29, 2018
Bio-Thera Solutions announced the company has filed an Investigational New Drug Application (IND) with the China National Medical Products Administration (NMPA) for the company's anti-Trop2 Antibody-Drug Conjugate (ADC)....

Previous page 1 2 3 4 Next page